Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO 2020
Research
Why 'hot' kidney tumors don't respond to PD-1 blockers
Dana-Farber scientists found genomic features that they say hamper the ability of kidney tumors to respond to the PD-1 inhibitors like Opdivo.
Angus Liu
May 29, 2020 11:00am
Allogene reports 63% response rate for off-the-shelf CAR-T
May 29, 2020 9:10am
Myovant details speedy effects of prostate cancer med relugolix
May 29, 2020 8:01am
Ziopharm's IL-12 gene therapy boosts survival in brain cancer
May 29, 2020 8:00am
GSK's anti-BCMA antibody gets a data boost ahead of FDA decision
May 27, 2020 9:00am
J&J links BCMA bispecific to 67% response rate in myeloma
May 18, 2020 8:40am
